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NURSING STANDARD
THE NEEDS OF cancer patients can be assessed easily and accurately using patient-reported health instruments (PHIs). Previously such tools were used purely for clinical research, but their role in clinical assessment and diagnosis has now been recognised (Department of Health (DH) 2008a). The Standard NHS Contracts for Acute Hospital, Mental Health, Community and Ambulance Services and Supporting Guidance 2008 (DH 2008b ) includes a requirement under section 5 for health providers to report on evidence from PHIs from April 2009. Data collected using PHIs are to be collected by providers pre-operatively and submitted to commissioners (DH 2008c) . There are a variety of generic, condition-specific and dimension-specific instruments available. The selection of instruments is a complex process. It is important to take into consideration their psychometric and practical properties. Nurses can enhance patients' quality of care by using PHIs. An understanding of the underlying philosophy of these tools and how they can be used in cancer care are important aspects of oncological nursing theory and practice.
Background
In England 242,200 new cases of malignant cancer (excluding non-melanoma skin cancer, were registered in 2006. Of these, 121,600 were in males and 120,600 in females (Office for National Statistics (ONS) 2008). Breast, lung, colorectal and prostate cancer accounted for more than half of these cases (ONS 2008) . Increased survival rates due to earlier detection of screening procedures have resulted in cancer becoming a chronic disease for a large proportion of patients (Cardy 2005) . Health-related quality of life (HRQoL) has therefore become an important consideration in the cancer journey (Cancer Research UK 2007) . It is now recognised that HRQoL outcomes are just as important as 'hard' outcomes such as mortality (Rosenbaum et al 2006) .
HRQoL is defined as 'a broad ranging concept incorporating in a complex way the person's physical health, psychological state, level of independence, social relationships, personal beliefs and their relationships to salient features of the environment' (World Health Organization (WHO) 1998). It is one of the most important factors to measure as an outcome in patients with cancer. It is a multidimensional concept, encompassing all the domains that are of importance to the individual, including physical ability, psychological wellbeing and social life. Clinical research examining the role played by psychosocial variables in the cancer experience has traditionally measured HRQoL as an endpoint and not a factor to be monitored throughout the diagnosis, treatment and terminal or remission process (Waalen 1990 
Summary
The measurement of health-related quality of life (HRQoL) is being increasingly advocated in healthcare practice, particularly in relation to cancer care. The use of patient-reported health instruments has been recommended in Lord Darzi's review of the NHS. Consequently, nurses have to be aware of the most reliable and valid QoL measurement tools for given situations and conditions. The aim of this article is to review the most common HRQoL tools for use in the oncology setting, highlighting the specific properties of each instrument. Measuring HRQoL using PHIs can be a useful process for oncology nurses or those carrying out research with cancer patients. In practice PHIs can help improve patient care by highlighting care needs, such as emotional and spiritual wellbeing, that would otherwise remain unknown. In research they can provide insight into subjective as opposed to objective outcomes. Bredin et al's (1999) study shows how these instruments can be used in practice and research. Patients diagnosed with lung cancer (n=116) were provided with a range of strategies, such as combining breathing control, activity pacing, relaxation techniques and psychosocial support. They completed various self-assessment questionnaires. These PHIs revealed significant improvements in breathing control, WHO performance status (WHO 1979) , levels of depression, physical symptom distress and breathlessness. In this instance, PHIs were used in research that could then inform practice. Further examples of such applications will be illustrated for specific, frequently used, cancer instruments.
There are many instruments available for assessing HRQoL, from generic (measuring multiple concepts relevant to a wide range of patients) to specific (a disease, population or health dimension (Table 1) ). They can be either patient-reported or clinician-reported instruments. Unless the patient is unable to complete the instrument, it is difficult to argue against patient-reported instruments being the most valuable in terms of capturing the patient experience. PHIs can enable patients to communicate their personal values, priorities, needs and expectations effectively in the context of their illness.
This article aims to identify the most common HRQoL PHIs used in oncology. The psychometric and practical properties of these instruments are discussed. Fitzpatrick et al (1998) have developed selection criteria for assessing the quality of PHIs (Table 2) . These criteria will be referred to in this review.
Method
The patient-reported bibliography Patient-Reported Outcome Measures, hosted by the National Centre for Health Outcomes Development at the University of Oxford, was searched for outcome measures used in oncology (http://phi.uhce.ox.ac.uk). The website includes a bibliography of more than 14,000 records of published instrument evaluations found on a number of electronic databases, such as the British Nursing Index, EMBASE, Medline and PsycINFO ® . The database was searched using the key term 'cancer' which generated 272 records. The inclusion criteria for records were that the population included in the research were adult cancer patients and that the properties of the instruments used were evaluated, which left 68 records for this review. The instruments discussed in this review elicited the greatest supporting evidence in terms of utility in the clinical environment.
Results
The identified HRQoL PHIs have been categorised into those that are condition-specific measuring generic HRQoL and those that are dimension-specific measuring various aspects of psychological wellbeing. Condition-specific instruments The most commonly used HRQoL instruments in oncology tend to have a generic and cancer-specific component, as is the case with the following three questionnaires.
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (Aaronson et al 1993) The 30-item EORTC QLQ-C30, developed by the European Organization for
Research and Treatment of Cancer Group, is a generic instrument developed to assess QoL in cancer patients. Nurses can use the questionnaire to assess changes in HRQoL throughout the cancer pathway and during or after a specific treatment regimen. There is therefore ample opportunity to identify negative disease or treatment side effects promptly (Bjordal et al 2000 , Greimel et al 2002 . The domains measured include role functioning and physical, psychological and social wellbeing. The tool is supplemented with disease-specific modules, for example breast, lung, head and neck, ovarian, gastric and cervical cancer, as well as multiple myeloma. Example items from each of the instrument domains are shown in Table 3 . Answers are provided on a scale of 1 = not at all, 2 = a little, 3 = quite a bit and 4 = very much. Some studies have found the reliability of the role functioning scale to be inadequate and have questioned whether it accurately measures the concept of role functioning. This was the case in a cohort of patients with non-resectable lung cancer (Aaronson et al 1993) and Dutch and Canadian patients with cancer (Osoba et al 1997) . However, other studies have found the questionnaire reliable, valid and sensitive to change in various patient groups (Osoba et al 1998 , McLachlan et al 1999 . Extensive use of the EORTC QLQ-C30 has demonstrated that it is valid in different countries (Apolone et al 1998 , Arraras et al 2002 and among long-term survivors (Apolone et al 1998) and palliative care patients (Kaasa et al 1995) . The instrument has demonstrated responsiveness to the effects of chemotherapy (Osoba et al 1994) , as well as palliative radiotherapy (Kaasa et al 1995) . Scales and items in the instrument have demonstrated discriminative validity with different types and stages of cancer (Arraras et al 2002) . The EORTC QLQ-C30 has been found to take less than 15 minutes to complete (Brédart et al 2005) and has demonstrated high completion rates in those with good performance status (Kobayashi et al 1998) as well as those with advanced cancer (Kaasa et al 1995) . The instrument is flexible in terms of time and cost and can be self-administered or undertaken during an interview.
Functional Assessment of Cancer TherapyGeneral (FACT-G) (Cella et al 1993)
The 27-item FACT-G measures multidimensional QoL, covering physical, social, emotional and functional wellbeing. It is appropriate for use with patients with any form of cancer. Nurses might find it useful in identifying symptom clusters (Paice 2004 , Gleason et al 2007 . As with the EORTC QLQ-C30, there are several scales that can be added to the FACT-G to measure disease and treatment-specific components of the cancer experience. Example items are shown in Table 4 . Answers are provided on a scale of strongly agree, agree, unsure, disagree and strongly disagree.
Reliability has been confirmed in a number of studies (Cella et al 1993 , Dapueto et al 2003 , Webster et al 2003 , Lee at al 2004 , Davies et al 2008 . The instrument has been validated for use with special populations, such as older people (Overcash et al 2001) , those living in (Winstead-Fry and Schultz 1997) , and among different cultures (Dapueto et al 2003 , Lee et al 2004 . The FACT-G has been found to be responsive to change in functional status over time (Webster et al 2003) and for this reason is often used in clinical trials (Cella et al 1993) . The instrument is appropriate for use in the general population and for a variety of health conditions and different types of cancer and cancer treatments (Brucker et al 2005) .
It has been found to discriminate between people receiving cancer treatment and those who are not (Overcash et al 2001) . The instrument and its subscales are specific enough to capture clinically relevant problems associated with a condition or symptoms and are general enough to allow for comparison between diseases. Respondent burden is minimal since the questionnaire is written at the reading level of a nine year old and the average completion time is five to ten minutes (Cella et al 1993) . The administrative burden is minimal, especially if self-administered as opposed to interview based. Computerised scoring programmes are available to aid the interpretation of patient scores.
Quality of Life in Adult Cancer Survivors (QLACS) (Avis et al 2005)
The QLACS is one of the few instruments that explores the longer-term effect of cancer, with its focus on survivorship as opposed to illness. Nurses might find this a useful measure for assessing HRQoL among long-term cancer survivors who are not captured by generic measures (Avis et al 2006) . The questionnaire consists of 47 items divided into seven generic QoL domains (negative feelings, positive feelings, cognitive problems, sexual problems, physical pain, fatigue and social avoidance) and five cancer-specific domains (appearance concerns, financial problems, distress over recurrence, family-related distress and benefits of cancer). Examples of items from each of these domains are shown in Table 5 . For each item respondents answer on a scale of 1=never, 2=seldom, 3=sometimes, 4=about as often as not, 5=frequently, 6=very often and 7=always.
The instrument's reliability and validity have been confirmed (Carver et al 2005 , Avis et al 2006 . In a methodological review of cancer QoL instruments, the QLACS was the only one to demonstrate test/retest reliability (Pearce et al 2008) . The questionnaire is responsive to long-term follow up of patients (Avis et al 2005) as well as life change (Avis et al 2006) . The instrument has shown precision in comparisons between cancer and non-cancer populations, and has the ability to distinguish between respondents in terms of health or illness (Avis et  al 2005) . Few data are available on the acceptability of the instrument. However, a response rate of 78% has been reported by the developers (Avis et al 2006) , which is consistent with response rates generally reported in follow-up studies of cancer survivors (Bloom et al 2004 , Carver et al 2005 . Dimension-specific instruments If nurses are more interested in, or concerned about, a specific dimension (Table 1) The scale has been demonstrated to be succinct, acceptable to respondents and reasonably concordant with clinical ratings. It has also distinguished consistently between the two subscales of anxiety and depression across studies (Herrmann 1997) . With a few exceptions, the HADS has demonstrated satisfactory reliability for the entire scale and for the anxiety and depression subscales (Moorey et al 1991 , Leung et al 1993 , Herrmann et al 1995 . Retest reliability is good (Michopoulos et al 2008) . The validity of the HADS has been shown in that its ability to detect clinical anxiety and depression is similar to that reported for other scales (Wilkinson and Barczak 1988 , Meakin 1992 , Ibbotson et al 1994 . The instrument has demonstrated responsiveness to psychopharmacological interventions, such as antidepressants and psychosocial interventions (Herrmann 1997) . The anxiety and depression subscales have been found to discriminate between groups of patients differing in tumour severity (Montazeri et al 2003) . A review of more than 200 studies using the HADS found that a large number of the studies reported 100% response rates (Herrmann 1997 ), indicating extremely high patient acceptability. The scale can be completed in two to six minutes and scored in one minute, making it ideal for hospital environments (Herrmann 1997) .
Despite the evidence supporting the use of the HADS in oncology, the instrument should be used with caution in patients coming to the end of the illness trajectory. Cancer progression often manifests with symptoms commonly associated with depression, such as fatigue, loss of appetite and reduced activity. Such symptoms are an inevitable consequence of terminal illness and are not necessarily indicative of depression. It is essential to consider such factors in interpreting responses to the HADS.
Mental Adjustment to Cancer Scale (MACS) (Watson et al 1988)
The MACS is a 40-item questionnaire designed to assess specific ways of responding to cancer. The instrument is widely used to determine the extent to which patients have adjusted to living with cancer. Nurses might find it useful in assessing how well patients are coping with their diagnosis or treatment (Stanton et al 2000 , Purushotham et al 2005 fatalism; and denial (avoidance). Examples of items from each of these subscales are outlined in Table 7 . Answers are provided on a scale of 'definitely does not apply to me', 'does not apply to me', 'does apply to me' and 'definitely does apply to me'. Data on the reliability of the MACS have been mixed. In a study of 632 patients with breast cancer, the fighting spirit and helpless/hopeless subscales were high on reliability, but the other subscales were less satisfactory (Osborne et al 1999) . The MACS has demonstrated validity when patient-reported outcomes are compared with spouse-reported outcomes (Watson et al 1988) and clinical outcomes (Greer et al 1989) . The instrument is also valid cross-culturally (Watson et al 1988 , Schwartz et al 1992 , Ferrero et al 1994 and for palliative care patients (Mystakidou et al 2005) . It has been found to correlate with instruments measuring the same concept (Osborne et al 1999) . The instrument demonstrates precision in its design, whereby mental adjustment and coping are measured as distinct concepts (Nordin et al 1999) . Ease of use has been maintained through the development of the 29-item Mini-MAC, which has been found to be a useful tool for obtaining rapid, reliable and economical assessment of mental adjustment to cancer (Watson et al 1994) . This is ideal for oncology settings.
Discussion
This article has considered three reliable PHIs measuring generic and condition-specific QoL, and two that focus on psychological wellbeing. With psychometric and practical properties, the three recommended condition-specific QoL instruments are the EORTC QLQ-C30 (Aaronson et al 1993) FACT-G (Cella et al 1993) , and the QLACS (Avis et al 2005) .
If nurses are interested in the current symptoms and experiences of the patient with cancer, then the first two are more appropriate. The QLACS is an ideal instrument for measuring the long-term experiences of such patients. The two recommended dimension-specific instruments are the HADS (Zigmond and Snaith 1983) and the MACS (Watson et al 1988) . The HADS is a reliable tool for identifying those patients with needs specific to the symptoms of anxiety and depression, which are frequently experienced by cancer patients. The MACS measures a similar health outcome, but in the form of adjustment to cancer. The HADS is recommended over the MACS because of the extensive, evaluative studies confirming its reliability and validity, as well as its acceptability to patients and nursing practices (Herrmann 1997 , Montazeri et al 2003 . Used in combination with more commonly employed nursing research methods, which are qualitative and naturalistic, and nursing practice designed to improve patient care and satisfaction, these instruments can provide nurses with greater understanding of individual patient needs and can enhance patient care.
Conclusion
This article is not comprehensive but does provide a thorough exploration of some of the most widely used HRQoL instruments in oncology. Nurses are advised to use the information alongside their own research to identify the most appropriate instrument for the desired outcome. It is advised that any subsequent reviews of potential health outcome instruments incorporate the selection criteria outlined in Table 1 (Fitzpatrick et al 1998) .
It is important to assess the needs of patients with cancer in terms of their overall health and wellbeing and their psychological wellbeing. PHIs should be used more widely in nursing research and practice (DH 2008a) . Many instruments are available, but not all are reliable and some might provide inaccurate assessments, acting as a burden to patients and nurses. Therefore it is necessary to understand the underlying philosophy behind these tools and be selective in choice. Nurses should think carefully about desired outcomes before administering the instrument so that they can make an informed decision about whether the chosen instrument is the most suitable for the patient, the nurse and the service being provided NS
